18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1213-1218

  De Giorgi, Ugo ^a,b   Mego, Michal ^a   Rohren, Eric M ^a   Liu, Ping ^a   Handy, Beverly C ^a   Reuben, James M ^a   Macapinlac, Homer A ^a   Hortobagyi, Gabriel N ^a   Cristofanilli, Massimo ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Bone metastases; Breast cancer; Circulating tumor cells; PET CT; Therapeutic monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADD ON THERAPY; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CELL COUNT; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SYSTEMIC THERAPY; TUMOR CELL; VISCERAL METASTASIS; BONE TUMOR; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; SCINTISCANNING; SURVIVAL; TUMOR EMBOLISM;

BONE NEOPLASMS; BREAST NEOPLASMS; CELL COUNT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASTIC CELLS, CIRCULATING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77956194618     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076455     Document Type: Article

References (20)

1. Solomayer E-F, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59:271-278. (Pubitemid 30243049)
2. Swenerton KD, Legha SS, Smith TL, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39:1552-1560.
3. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986;58:2589-2593.
4. Sherry MM, Greco FA, Johnson DA, Hainsworth JD. Metastatic breast cancer confined to the skeletal system: an indolent disease. Am J Med. 1986;81:381-386.
5. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol. 2002;29(3, suppl 11):134-144.
6. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712-720.
7. Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189-196.
8. 18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-3447.
9. Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.
10. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010;21:33-39.
11. Mawlawi O, Podoloff DA, Kohlmyer S, et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med. 2004;45:1734-1742. (Pubitemid 47618484)
12. 18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303-3311.
13. Allard WJ, Matera J, Miller MC. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res. 2004;10:6897-6904.
14. Meng S, Tripathy D, Shete S, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA. 2006;103:17361-17365.
15. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11:R59.
16. Reuben JM, Lee BN, Li C, et al. Genomic of circulating tumor cells in metastatic breast cancer. J Clin Oncol. 2007;25(June 20 suppl):1002.
17. Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol. 2008;19:891-897.
18. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420-1430. (Pubitemid 46260029)
19. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging: predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403-6409. (Pubitemid 44799711)
20. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;31:5153-5159.